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WHITE MATTER ALTERATIONS AND COGNITIVE CORRELATES IN THE 
EARLY COURSE OF SCHIZOPHRENIA 
RACHAL R. HEGDE 
ABSTRACT 
 
Background: White matter (WM) aberrations have been broadly characterized in 
schizophrenia using standard diffusion tensor imaging (DTI) techniques. The present study 
aims to distinguish WM alterations in the early course of schizophrenia using advanced 
diffusion measures of free-water corrected fractional anisotropy (FAt) and free-water 
fractional volume (FW), in addition to examining their association with neurocognition, 
social cognition, and clinical measures. We report baseline results from a longitudinal 
study investigating the effects of cognitive enhancement therapy (CET) on brain structure 
and function in schizophrenia. 
 
Methods: The sample consisted of 46 early course schizophrenia patients and 20 healthy 
controls. Diffusion-weighted images were processed using a free-water imaging pipeline, 
that separately models diffusion of water in tissue (FAt) and the extracellular space (FW). 
Tract-Based Spatial Statistics was performed on the FAt and FW diffusion tensor maps and 
average measures from 24 bilateral regions of interest (ROIs) were extracted. We examined 
WM structural differences between patients and controls and further investigated WM 





Results: Patients showed significant FAt reductions in the body of the corpus callosum, 
posterior thalamic radiation (PTR), cingulate gyrus, anterior corona radiata, corpus 
callosum, and corona radiata and FW elevations in the posterior corona radiata (PCR), 
uncinate fasciculus (UNC), and PTR compared to controls. For patients, positive 
correlations between FAt and working memory were observed in the PCR and fornix & 
stria terminalis (FXST). Negative associations between FW and attention/vigilance were 
observed in the UNC. Positive correlations between FAt and theory of mind (ToM) were 
observed in average whole-brain and FXST. Negative associations between FW and ToM 
were observed in average whole-brain and PCR. Positive correlations between FW and 
negative symptom severity were observed in the external capsule. 
 
Conclusion: Using free-water imaging, we report WM aberrations and FW elevations in 
the early course of schizophrenia in addition to neural correlates associated with cognition 
and clinical measures. Future investigations on the longitudinal effects of CET are 
warranted for a greater understanding of the underlying neural correlates of clinical 
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Schizophrenia (SZ) is a chronic, complex neuropsychiatric disorder affecting 
approximately 1% of the global population (American Psychiatric Association, 2013). 
According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition 
(DSM-5) and as further summarized in Table 1, diagnostic criteria for SZ must include two 
or more of the following for a significant duration of time over 1-month: delusions, 
hallucinations, disorganized speech, disorganized or catatonic behavior, or negative 
symptoms. Furthermore, at least one of the symptoms must include one of the first three 
criteria listed in Table 1 (American Psychiatric Association, 2013; Freedman, 2003).  
 
Table 1: Diagnostic Features of Schizophrenia. Table with criteria for diagnosing 






SZ symptoms are further classified into positive and negative symptoms. Positive 
symptoms are defined as psychotic behaviors, including: hallucinations, delusions, thought 
disorders, and movement disorders. Negative symptoms are defined as disruptive 
emotional and behavioral processing such as: flat affect, anhedonia, avolition, and alogia 
(American Psychiatric Association, 2013). 
 
Structural Brain Abnormalities in Schizophrenia 
Although there is a limited understanding of the pathophysiology of SZ, potential 
mechanisms underlying progressive brain volume deficits include abnormal 
neurotransmission, neuropil abnormalities, and stress-related hypothalamic-pituitary-
adrenal functional hyperactivity (Busatto, Zanetti, Schaufelberger, & Crippa, 2010). 
Several histopathological studies have also consistently identified the presence of altered 
myelin and oligodendrocyte pathology in SZ (Davis et al., 2003; Konrad & Winterer, 2007; 
Segal, Koschnick, Slegers, & Hof, 2007; Torrey, Webster, Knable, Johnston, & Yolken, 
2000).  
As brain structural abnormalities are commonly associated with SZ, several 
longitudinal magnetic resonance imaging (MRI) studies have compared neuronal structure 
of SZ participants with healthy controls (HC) in order to investigate disruptions in neuronal 
development. SZ typically appears to display enlarged lateral and third ventricles, 
increased cerebrospinal fluid space, and volumetric reduction in several brain regions such 
as the hippocampus, superior temporal cortex, frontal and temporal gray matter (GM), as 
well as abnormalities in white matter (WM) (Busatto et al., 2010; Freedman, 2003). These 
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defining features exemplify disrupted neuronal development, some of which are thought 
to predate the onset of SZ illness. 
 Van Erp et al. (2015) conducted a meta-analysis investigating patterns of 
subcortical brain abnormalities between SZ and HC reporting SZ had localized volumetric 
reductions in the hippocampus, amygdala, thalamus, accumbens, and total intracranial 
volume. Van Erp et al. (2018) further went on to conduct a meta-analysis examining 
cortical thickness and surface area abnormalities between SZ and HC. The study noted 
neuroanatomical abnormalities in SZ are regionally specific with SZ having a widespread 
thinner cortex and reduced cortical surface area. 
Evidence from prior studies have also reported correlations between WM volume 
and volumetric reduction in both temporal and frontal lobe regions suggesting potential 
relations between WM and GM pathology (Kubicki et al., 2007). Several studies have 
additionally shown correlations between volumetric reductions in frontal GM and WM 
brain regions with the degree of psychotic severity (Banaj et al., 2018). As neuronal 
circuitry and functional connectivity between various brain regions rely on WM, 
underlying cerebral WM connections are considered to contribute to the pathophysiology 
of SZ (Ellison-Wright & Bullmore, 2009; Hong & Kochunov, 2014; Samartzis, Dima, 
Fusar-Poli, & Kyriakopoulos, 2014). 
In 1906, Carl Wernicke initially proposed SZ to be associated with disruptive 
association fibers in the brain and recently SZ has been hypothesized to be a disorder of 
disrupted connectivity involving aberrant communication between functional brain regions 
(Karl J. Friston, 1998; Karl J Friston, 2002). Current advancements in neuroimaging 
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techniques and analysis including functional connectivity and diffusion tensor imaging 
(DTI) have allowed research to further support this hypothesis (K. J. Friston & Frith, 1995). 
These defining features exemplify disrupted neuronal development, some of which 
are thought to predate the onset of SZ illness (Busatto et al., 2010; Freedman, 2003). 
Through neuroimaging analysis, studies have shown correlations between structural 
abnormalities and clinical manifestations including cognitive deficits and neuropsychiatric 
impairments. Thus, greater insight into understanding the process through which brain 
connectivity disruptions lead to neuropsychiatric impairments and clinical manifestations 
via WM alterations are warranted. 
 
White Matter and Diffusion Tensor Imaging 
Diffusion MRI has revolutionized diagnostic imaging. Diffusion-weighted imaging 
(DWI) evaluates the microarchitecture of the brain by providing signal contrast based on 
the quantification of water diffusion in brain tissue, a method known as Brownian motion. 
Water diffusion is defined as isotropic when diffusion is considered equal in all directions 
and defined as anisotropic when diffusion is restricted in certain directions (Pierpaoli, 
Jezzard, Basser, Barnett, & Di Chiro, 1996).  
Diffusion Tensor Imaging (DTI) allows for the assessment of spatial organization 
of tissue orientation by examining the three-dimensional shape of diffusion as a 3x3 matrix 
comprising a diffusion tensor representing location, orientation, and anisotropy of the 
brain’s WM tracts (Kubicki et al., 2007; Pierpaoli et al., 1996). Fractional anisotropy (FA), 
considered an index of neuronal integrity, reflects both the organization of WM tracts and 
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myelination of axon fibers. Secondary measures include mean diffusivity (MD), radial 
diffusivity (RD), and axial diffusivity (AD). MD is the average diffusion rate across all 
fiber orientations within a tract; AD is considered to be an indicator of myelination as it 
measures the diffusion rate along fiber orientations of an axon; and RD measures the 
diffusion rate perpendicular to the fiber orientation (Pierpaoli et al., 1996).  
From DTI analyses, studies have found decreased FA in prefrontal and temporal 
lobes, aberrations within fiber bundles connecting both regions, and recurrent WM tract 
disruptions in patients with SZ (Karlsgodt, Sun, & Cannon, 2010; Kubicki et al., 2007; 
Wheeler & Voineskos, 2014). These disruptions of WM networks contribute to the 
structural connectivity abnormalities present from preclinical to chronic stages of SZ, 
resulting in significant clinical manifestations and cognitive deficits (Canu, Agosta, & 
Filippi, 2015; Karlsgodt, Sun, et al., 2010; Kubicki et al., 2007; Szeszko et al., 2007). 
 
Free-Water Imaging 
DTI indices, such as FA, are highly sensitive to biological pathologies such as 
axonal degeneration and elevated extracellular free-water (FW). FW can be defined as 
diffusing water molecules free of restriction or hinderance from surrounding tissues, and 
therefore, are not recommended to be regarded as specific markers for WM microstructural 
changes (Alexander, Lee, Lazar, & Field, 2007; Assaf & Pasternak, 2008; Pierpaoli et al., 
1996).  
Free-water imaging (FWI) is a novel technique offering increased sensitivity to the 
detection of structural changes in WM as it corrects for FW contamination in the DTI 
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acquisition schemes. FW is considered to be an indicator of extracellular changes due to 
the contribution of pathologies such as atrophy, edema, or neuroinflammation (Pasternak, 
Sochen, Gur, Intrator, & Assaf, 2009). Free-water corrected FA (FAt) reductions are found 
to be limited to frontal lobe WM while FW is shown to exhibit global increases in first-
episode patients (Lyall et al., 2017; Pasternak et al., 2012). Chronic SZ, however, is found 
to be associated with widespread FAt reductions with limited FW elevations, indicating 
increased WM deterioration (Oestreich et al., 2017a; Pasternak, Westin, Dahlben, Bouix, 
& Kubicki, 2015). The application of FWI allows researchers to identify WM changes in 
SZ related to developmental change, cognition, and symptomatology. Investigating neural 
correlates with measures of FAt and FW is critical as prior findings have revealed 
extracellular changes play a significant role in early stages of SZ and progress to increased 
WM deterioration overtime.  
 
Cognitive Deficits in Schizophrenia 
 Neurocognitive impairments are often present prior to the onset of psychosis and 
are prevalent in domains of attention, executive function, memory, learning, and social 
cognition (Barch, 2004; Nuechterlein et al., 2004). Cognitive decline in SZ is a significant 
risk factor to consider as neuropsychological deficits serve as potential indicators of the 
severity and progression of SZ. The US National Institute of Mental Health (NIMH) 
developed the Measurement and Treatment Research to Improve Cognition in 
Schizophrenia (MATRICS) consensus which includes attention/vigilance, working 
memory, verbal learning and memory, visual learning and memory, reasoning and problem 
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solving, processing speed, and social cognition subdomains relevant to SZ research in order 
to address cognitive decline in SZ (Nuechterlein et al., 2008).  
In addition to neurocognitive impairments, social cognition appears to be a major 
determinant of functional disabilities in schizophrenia (Brekke, Hoe, Long, & Green, 2007; 
Fett et al., 2011; Michael Foster Green, Kern, Braff, & Mintz, 2000; Kennedy & Adolphs, 
2012) and is further thought to be a mediator of the relation between neurocognition and 
functional outcome (Couture, Penn, & Roberts, 2006). Social cognitive impairments have 
been well documented in SZ, yet there is a limited understanding of social cognitive 
domains. Social cognitive processes which are known to be impaired in SZ include 
mentalizing, social perception, social knowledge, attributional biases, and emotion 
(Michael F Green, Olivier, Crawley, Penn, & Silverstein, 2005). Mentalizing, also known 
as theory of mind (ToM), is of great interest and is suggested to be a greater predictor of 
functional outcome than neurocognition (Fett et al., 2011), making it an important 
therapeutic target for early intervention.  
 
White Matter Correlates of Cognitive Deficits in SZ 
DTI studies have shown that altered structural WM integrity in frontal and temporal 
brain regions and FA reduction in numerous WM tracts in frontal-temporal connections 
are correlated with cognitive impairment in executive functioning (Haller, Padmanabhan, 
Lizano, Torous, & Keshavan, 2014; Wheeler & Voineskos, 2014). WM forms a crucial 
component of the human connectome (Sporns, Tononi, & Kötter, 2005) and transfers 
information within dispersed neural networks functioning in cognitive operations (Filley 
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& Fields, 2016). Working memory impairments have been directly linked to WM 
alterations in SZ (Karlsgodt, Kochunov, et al., 2010; Karlsgodt, Niendam, Bearden, & 
Cannon, 2009; Nazeri et al., 2013). Previous studies have reported associations between 
neurocognitive impairments and specific WM regions and processing speed (Kochunov et 
al., 2016; Kochunov et al 2017; Roalf et al., 2013). Furthermore, Lyall et al. (2017) is the 
only present study to examine neurocognitive correlates in relation to FW in SZ and 
proposes elevated extracellular FW as a predictor of better functional outcomes in first 
episode psychosis.  
While there is a growing literature on WM alterations in relation to neurocognition 
in SZ, little is known about WM alterations and social dysfunction. Research suggests that 
the frontal cortical regions and the corpus callosum play essential roles in social 
functioning (Koshiyama et al., 2018; Miyata et al., 2010). To our knowledge, no study has 
examined social cognitive correlates of FAt and FW in SZ. 
 
Cognitive Remediation Therapy 
Although antipsychotics have been helpful in the treatment of positive symptoms, 
they are unable to treat negative symptoms, cognitive impairments, and functional deficits 
in SZ (Patel, Cherian, Gohil, & Atkinson, 2014). This has led to a substantial interest in 
developing non-pharmacological interventions in SZ (Andreou & Moritz, 2016). Cognitive 
remediation therapy (CRT) is a behavioral training-based non-pharmacological 
intervention designed to improve cognitive functioning and behavior with a further aim to 
improve psychosocial and community functioning (Keshavan, Vinogradov, Rumsey, 
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Sherrill, & Wagner, 2014). The majority of CRT programs typically focuses on targeting 
either neurocognition or social cognition but some cognitive therapies like cognitive 
enhancement therapy (CET) focus on a more integrated approach of both neurocognitive 
and social cognitive factors for maximal treatment outcomes (Eack et al., 2009; Hogarty 
GE, Flesher S, Ulrich R, & et al, 2004). CET includes elements of executive training as 
well as sociocognitive components in order to address cognitive dysfunction and social 
difficulties underlying positive and negative symptomatology in schizophrenia (Hogarty & 
Flesher, 1999). 
CRT has proven to be an effective intervention for cognitive impairments in 
addition to improving daily functioning in SZ (Wykes, Huddy, Cellard, McGurk, & 
Czobor, 2011). Collectively, evidence from neuroimaging studies indicate both structural 
and functional changes in major prefrontal brain regions (Keshavan et al., 2014; Thorsen, 
Johansson, & Løberg, 2014). CRT is a promising option as abnormal prefrontal cortical 
activity tends to be associated with impairments in several cognitive domains (Keshavan 
et al., 2014; Thorsen et al., 2014). Although knowledge of the underlying neural 
mechanisms of CRT is limited, evidence from studies indicate strengthened compensatory 
structures and promotion of growth and connectivity through neuroplasticity, supporting 
the beneficial abilities of CRT to preserve both neurobiological and cognitive factors 
(Minzenberg MJ, Laird AR, Thelen S, Carter CS, & Glahn DC, 2009).  
While there is a growing literature on CRT’s effects on GM, Penadés et al. (2013) 
is the only present study to examine CRT’s effects on WM changes in SZ, reporting 
evidence for increased FA in the genu of the corpus callosum and the posterior thalamic 
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radiation after CRT. Structural changes further support the hypothesized beneficial effects 
of CRT’s aim to minimize the progressive degradation of brain damage in SZ. However, 
in order to develop effective treatment strategies for SZ, a greater understanding of neural 





Currently there is a limited understanding of the etiology and underlying 
neurobiological basis of SZ. As SZ is proposed to be a disorder of dysconnectivity, neural 
network disruptions may lead to cognitive impairments and clinical manifestations. A 
greater understanding of the microstructural WM alterations and their associations to both 
cognitive and clinical correlates may lead to earlier diagnosis and treatment to reduce the 
severity and progression of SZ symptoms.  
This study first aims to delineate WM structural abnormalities between SZ and HC 
using FAt and FW measures through DTI analysis. We hypothesize that early course SZ 
will have greater FAt reductions and elevated FW compared to HC. In order to better 
understand structural changes in SZ at various stages, early course SZ will further be 
classified into early stage and later stage SZ based on a 2-year duration of illness cut-off.  
Our secondary objective is to examine WM relations to neurocognition, social 
cognition, and clinical symptom severity in SZ. As the literature is limited with regards to 
the association of FAt and FW measures with clinical manifestations in SZ, we further aim 
to identify potential neural correlates associated with cognition and clinical measures 
which may serve as biomarkers for predicting improvements following CET. 
Identification of WM aberrations in the early stages of SZ may be a fundamental 
pathophysiological mechanism underlying clinical presentation of SZ before the 
appearance of clinical symptoms. Thus, a greater understanding of these neurobiological 
mechanisms is critical for developing intervention strategies to preserve brain structure and 





Participants were recruited through the National Institute of Mental Health (NIMH) 
funded study: Brain Imaging, Cognitive Enhancement and Early Schizophrenia (BICEPS). 
Participants were selected as part of a baseline assessment of a dual site (Boston and 
Pittsburgh) randomized-controlled study (NCT #01561859) examining the effects of CET 
in early course SZ. The study received ethics committee approval from The University of 
Pittsburgh and Beth Israel Deaconess Medical Center. Participants signed a written, 
informed consent prior to participation.  
This sample included 46 patients within the early course SZ and 20 HC (see Table 
2). HC participants had an average age of 25.5 (SD=4.2) years and patients had an average 
age of 25.9 (SD=6.4) years. Samples of controls and patients were 60.9% and 75% males, 
respectively. The mean age of onset and duration of illness across SZ were 21.9 (SD=5.1) 
and 3.9 (SD=2.1) years, respectively. The mean total SAPS and SANS across SZ were 0.3 
(SD=0.4) and 1.3 (SD=0.8), respectively. The CPZ mean dose equivalent was 390.3 
mg/day (SD=264.1). 
Inclusion criteria required participants to be between 18-45 years of age, have an 
IQ>80 as assessed using the WASI-II (Hays, Reas, & Shaw, 2002), an ability to read at a 
6th grade level or higher, and speak fluent English. Patients were included if they had a 
diagnosis of SZ or schizoaffective disorder and was further verified using the SCID 
interview, duration of psychotic symptoms <8 years, stabilized on antipsychotic 
medication (assessed via SCID and medical history). Exclusion criteria included reported 
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history of significant neurological disorders that may produce cognitive impairment (e.g., 
seizure disorder, traumatic brain injury), persistent suicidal or homicidal behavior, recent 
history of substance abuse or dependence (within the past 3 months), MRI 
contraindications, and decisional incapacity requiring a guardian. HC were also excluded 
if they had major psychiatric illness or family history of psychosis. 
 
 
Neuropsychological & Clinical Test Measures 
 
Neurocognition 
The Measurement and Treatment Research to Improve Cognition in Schizophrenia 
(MATRICS) cognitive battery for clinical trials was administered to assess for 
neurocognitive functioning. The cognitive battery measures reasoning & problem solving, 
processing speed, attention & vigilance, working memory, verbal learning & memory, 
visual learning & memory, and social cognition (Nuechterlein et al., 2004). The social 
cognition score was evaluated from the Mayer-Salovey-Caruso Emotional Intelligence 
Test (MSCEIT) total score (Mayer, Salovey, Caruso, & Sitarenios, 2003). T-scores were 
corrected for age and sex and composite scores were then derived for each domain.  
 
Social Cognition 
As social cognition is multidimensional, we implemented three factors of social 
cognition, specifically derived from the current sample of early course schizophrenia 
patients. These factors were determined from 11 validated data subsets assessing domains 
of social cognitive skills in 90 patients with early course schizophrenia and is further 
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described in detail in Mike et al. (2019). The three factors assess for Emotion Management, 
Theory of Mind (ToM), and Emotion Perception and classification of these domains was 
based on MATRICS recommendations (Green et al., 2005). 
 
Clinical measures 
Patients’ positive and negative symptom severity were assessed using the Scale for 
the Assessment of Positive Symptoms (SAPS) (Andreasen, 1984b) and the Scale for the 
Assessment of Negative Symptoms (SANS) (Andreasen, 1984a), respectively. Higher 
scores on these measures indicate more severe symptomology. 
 
 
Diffusion MR Procedures 
 
Diffusion MRI scans were acquired at the University of Pittsburgh on a 3.0 T 
Siemens Trio Imaging Systems scanner. A total of 87 diffusion-weighted images were 
obtained from each subject. Multi-shell dMRI was acquired with 6 gradient directions at 
b=100 s/mm2, 10 at 400 s/mm2, and 80 at 900 s/mm2 with 2mm isotropic voxels. 
 
Image Acquisition and Processing  
Free Water Imaging 
The Free Water Imaging analysis pipeline was executed following the methods 
described in detail by Pasternak et al. (2009). Diffusion-weighted images were corrected 
for motion, eddy-current artifacts, and masking of the diffusion MRI. The FW imaging 
maps were generated by fitting the aligned diffusion-weighted images with a two-
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compartment model comprising a FW compartment and a tissue compartment (Pasternak 
et al., 2009). The FW compartment accounts for the fractional volume of FW found in 
extracellular space whereas the tissue compartment accounts for the signal left after 
eliminating contribution of freely diffusing water. The FAt parameter enables more 
accurate estimations of tissue specific FA measures as the signal contribution from 
extracellular space is attenuated. 
 
White Matter Processing 
WM was investigated using whole-brain Tract-Based Spatial Statistics (TBSS) 
according to the ENIGMA-DTI Working Group protocol 
(http://enigma.ini.usc.edu/ongoing/dtiworking-group/). A detailed description of the TBSS 
procedure is provided by Smith et al. (2006). FA images from all participants were co-
registered into the ENIGMA-DTI template (Jahanshad et al., 2013). Each participant’s 
aligned FA image was then projected onto the ENIGMA-DTI skeleton using non-linear 
registration creating a skeletonized FA map. Regions of interest (ROI) were parcellated 
from the ENIGMA-DTI target, defined according to the Johns Hopkins University WM 
atlas calculating average FA for each ROI (Mori et al., 2008; Oishi et al., 2008). We 
selected for all 24 bilateral ROIs and average FAt and FW across the entire skeleton. Mean 
FAt and FW values were extracted for all bilateral ROIs and whole brain. The 24 bilateral 
ROIs include: anterior corona radiata (ACR); anterior limb of internal capsule (ALIC); 
body of corpus collosum (BCC); corpus callosum (CC); cingulum (cingulate gyrus) 
(CGC); cingulum (hippocampal portion) (CGH); corona radiata (CR); corticospinal tract 
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(CST); external capsule (EC); fornix (FX); fornix & stria terminalis (FXST); genu of the 
corpus callosum (GCC); internal capsule (IC); inferior fronto-occipital fasciculus (IFO); 
posterior corona radiata (PCR); posterior limb of internal capsule (PLIC); posterior 
thalamic radiation (PTR); retrolenticular part of internal capsule (RLIC); splenium of 
corpus collosum (SCC); superior corona radiata (SCR); superior front-occipital fasciculus 




All statistical analyses were conducted using R (version 3.5.1, https://www.r-
project.org/). We used t-tests and Chi square tests to compare demographic data between 
patients and controls.  
To investigate group comparisons (2 levels: HC, SZ) for FAt and FW of bilateral 
tracts as well as for neurocognitive differences, we performed an analysis of variance 
(ANOVA). A Spearman correlation was also performed to assess the effects of illness 
duration. As early course schizophrenia displayed a bimodal distribution for duration of 
illness, we further separated the heterogeneity effects in early course schizophrenia into 
two subgroups: early stage (<2 years) and later stage (>2 years). A secondary ANOVA was 
run comparing early stage SZ, later stage SZ, and HC. Effect sizes were calculated with 
Cohen’s d and age and sex were used as covariates for all analyses. Race and education 
were also included as covariates for neurocognitive performance. We chose to include 
education rather than IQ as a covariate for neurocognitive performance since education 
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was significantly different between patients and controls. For social cognitive performance, 
only race was included as an additional covariate as race has been shown to be linked to 
social cognitive performance in schizophrenia (Pinkham, Kelsven, Kouros, Harvey, & 
Penn, 2017).  
We ran Spearman correlations correcting for ROIs within neurocognitive, social 
cognitive, and clinical measures to investigate associations between all ROIs and both 
cognitive and clinical correlates. All p-values were adjusted for False Discovery Rate 





As illustrated in Table 2, there were a total of 66 subjects (SZ=46, HC=20). Patients 
and controls were matched on age, sex, race, and IQ, but differed for education (Table 2). 
 






 N N X2 p-value 
Sex (Male/Female) 28/18 15/5 0.7 0.409 
Race (CA/AA/OT) 29/14/3 14/5/1 3.9 0.278 
 Mean SD Mean SD F p-value 
Age (years) 25.9 6.4 25.5 4.2 53.9 0.809 
Education* 13.8 2.1 15.6 2.4 31.3 0.006 
IQ 106.6 11.0 107.7 13.9 29.8 0.77 
Age of Onset 21.9 5.7 - - - - 
Illness Duration 3.9 2.2 - - - - 
SAPS Total Score 0.3 0.4 - - - - 
SANS Total Score 1.3 0.8     
Daily CPZ equivalents (mg/day) 390.3 264.1 - - - - 
Notes: SZ, Schizophrenia; HC, Healthy Controls; SD, Standard Deviation; AA, African American; CA, 
Caucasian; OT, Other; SAPS, Scale for the Assessment of Positive Symptoms: SANS, Scale for the 









White Matter Microstructural Differences in FAt and FW  
Of the 25 regions, SZ showed FAt reductions in 6 regions. The largest effect sizes 
were detected in the BCC, followed by the PTR, CGC, ACR, CC, and the CR (Figure 2, 
Supplementary Table 1). However, effects did not survive FDR correction. 
 
 
Figure 1. Effect sizes for FAt differences between SZ and HC. Circles indicate Cohen’s 
d and horizontal lines indicate 95% confidence interval (CI). Data was covaried for age 







SZ also showed elevated FW in 3 regions. The largest effect sizes were observed 
in the PCR, followed by the UNC, and the PTR (Figure 3, Supplementary Table 2). 




Figure 2. Effect sizes for FW differences between SZ and HC. Circles indicate Cohen’s 
d and horizontal lines indicate 95% CI. Data was covaried for age and sex. Displaying 





Figure 3. White matter microstructural differences in SZ compared to HC. Effect 
sizes between SZ and HC for A) FAt and B) FW. Colors indicate Cohen’s d (adjusted for 
age and sex). Data visualization through ENIGMA-Viewer (Zhang et al., 2017). 
 
White Matter Differences in FAt and FW in Relation to Illness Duration 
To assess the potential impact of illness duration on WM changes in SZ, we carried 
out correlations between illness duration and FAt and FW. No significant associations were 
found for illness duration and age of onset for FAt and FW in SZ. The SZ group was then 
further divided into early (n=13) and later (n=33) stage subgroups in order to detect for 
subtle microstructural changes sensitive to duration of illness.  
In the SZ sub-group analysis, no significant differences in FAt were detected 
between early stage SZ and HCs. However, early stage SZ showed significantly higher FAt 
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compared to later stage SZ in the BCC, followed by CGH, and average whole-brain FAt 
(p<0.05, FDR correction). Furthermore, later stage SZ showed significant FAt reductions 
compared to HCs in the PTR, followed by the BCC, CGC, ACR, FXST, CR and average 
whole-brain FAt (p<0.05, FDR correction) (Figure 4, Supplementary Table 3). 
 
 
Figure 4. FAt distinctions between SZ stages and HC. Effect sizes for FAt measures in 
early stage SZ vs HC, early stage SZ vs later stage SZ, and later stage SZ vs HC. Data was 







FW in the FX was significantly elevated in early patients compared to HCs (p<0.05, 
FDR correction). In comparison, later stage patients showed significantly elevated FW in 
the PCR compared to HC (p<0.05, FDR correction) (Figure 5, Supplementary Table 4). 




Figure 5. FW distinctions between SZ stages and HC. Effect sizes for FW measures in 
early stage SZ vs HC, early stage SZ vs later stage SZ, and later stage SZ vs HC. Data was 







Neurocognitive Differences Between Schizophrenia and Healthy Controls 
SZ performed lower in all cognitive domains in comparison to HC with the 
exception of the visual learning and memory domain. However, this finding did not reach 
statistical significance. SZ displayed significantly lower neurocognitive performance for 
speed of processing, verbal learning and memory, social cognition, and reasoning and 
problem solving (p<0.05) (Figure 6, Supplementary Table 5). However, reasoning and 
problem solving did not survive after FDR correction.  
 
 
Figure 6. Effect sizes for neurocognitive differences between SZ and HC. Circles 
indicate Cohen’s d and horizontal lines indicate 95% CI. Data was covaried for age, sex, 





Relations Between White Matter and Neurocognition in Schizophrenia 
To investigate whether WM changes were associated with neurocognition in SZ, 
we conducted correlations between neurocognitive domain scores and FAt and FW across 
all ROIs. Significant positive correlations were observed between working memory and 
FAt for CGH, FXST, and PCR (p<0.05). However, only associations between working 




Figure 7. Significant ROIs associated with working memory in SZ. The FAt of the 
FXST and the PCR were positively correlated with working memory. Data was covaried 





Significant negative correlations were observed between attention/vigilance and 
FW for the UNC (p<0.05, FDR correction). Negative associations were also seen between 
working memory and FW for the CGH and PLIC. However, only associations between 
attention/vigilance and UNC survived FDR correction (Figure 8, Supplementary Table 6). 
 
 
Figure 8. Uncinate Fasciculus (FW) & attention/vigilance in SZ. The FW of the UNC 
was negatively correlated with attention/vigilance. Data was covaried for age, sex, race, 








Relations Between White Matter and Social Cognition in Schizophrenia 
To investigate whether WM changes were associated with social cognition in SZ, 
we conducted correlations between three social cognition factors and FAt and FW across 
all ROIs. Positive correlations were observed between ToM and FAt for average whole-
brain FAt, FXST, IC, PLIC, SCR, and UNC (p<0.05) (Supplementary Table 7). However, 
only associations between ToM and FAt for average whole brain FAt and FXST survived 
FDR correction (Figure 9 & Figure 10).  
 
 
Figure 9. Average FAt & ToM in SZ. The average FAt was positively correlated with 






Figure 10. Fornix & Stria Terminalis (FAt) & ToM in SZ. The FAt of the FXST was 
positively correlated with ToM. Data was covaried for age, sex, and race. Displaying FDR 
corrected p-values (P<0.05). 
 
Negative correlations were observed between ToM and FW for average whole-
brain, ACR, CGC, CR, CST, GCC, IC and PCR (p<0.05) (Supplementary Table 8). 
Negative associations were also seen between emotion recognition and FW for the CGH. 
Only associations between ToM and FW for average whole-brain and PCR survived FDR 




Figure 11. Average FW & ToM in SZ. The average FW was negatively correlated with 







Figure 12. Posterior Corona Radiata (FW) & with ToM in SZ. The FW of the PCR was 
negatively correlated with ToM. Data was covaried for age, sex, and race. Displaying FDR 
corrected p-values (p<0.05). 
 
Relations Between White Matter and Clinical Symptomatology in Schizophrenia 
To investigate whether WM alterations were correlated with positive and negative 
symptom severity in SZ, we conducted correlations between symptom severity scores from 
SAPS and SANS and FAt and FW across all ROIs. We saw positive correlations between 
the SAPS total score and BCC and SLF (p<0.05) (Supplementary Table 9). However, these 
correlations did not survive after FDR correction. Significant positive correlations were 
observed for the EC and SANS total score for FW (p<0.05, FDR correction) (Figure 13). 






Figure 13. External Capsule (FW) & negative symptoms in SZ. The FW of the EC 
was positively correlated with SANS. Data was covaried for age and sex. Displaying 






We report WM differences in interhemispheric, thalamocortical, and limbic tracts 
between SZ and HC in measures of both FAt and FW. We also report FAt and FW relations 
between cognition and clinical symptoms in patients. Positive correlations were observed 
between FAt and working memory in the PCR and FXST as well as negative correlations 
between FW and attention/vigilance in the UNC. Positive associations between FAt and 
ToM were shown in average whole-brain and FXST in addition to negative associations 
between FW and ToM for average whole-brain and PCR. Furthermore, positive 
correlations between FW and negative symptoms were observed in the EC. 
 
Microstructural Aberrations in FAt and FW 
We report WM FAt aberrations and FW elevations in SZ compared to HC. 
Specifically, largest effects were observed for FAt reductions in the BCC, CGC, PTR, 
ACR, CC, and CR, all showing Cohen’s d magnitudes of >0.5 (medium effect sizes). 
Although structural differences did not survive correction for multiple comparisons, our 
uncorrected FAt findings align with previous studies reporting FA reductions of the CC 
and CR (Ellison-Wright & Bullmore, 2009; Kubicki et al., 2007). Furthermore, a meta-
analysis by the ENIGMA-DTI Working Group found significant FA reductions 
predominantly in frontotemporal, interhemispheric, and thalamocortical regions, with 
largest effects in the CC, specifically in the BCC, and in the CR (Kelly et al., 2017).  
As early stages of SZ are associated with increased extracellular volume, we 
expected to see elevated FW for our early course patient sample. We report higher FW 
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values in patients compared HC, with largest effects detected for PCR, UNC, and the PTR, 
all showing Cohen’s d magnitudes of >0.5 (medium effect sizes). While a main effect of 
global FW elevations for patients was observed, our uncorrected findings align with 
previous studies showing similar effects in first-episode patients (Lyall et al., 2017; 
Pasternak et al., 2012). 
As FAt and FW are considered to be sensitive to illness duration, we separated early 
course SZ into early and later stages based on illness duration of 2 years in an attempt to 
detect subtle microstructural differences which may be related to the progression of SZ. 
Early stage SZ appeared to have significantly greater FAt in the FXST, CGH, and average 
whole-brain FAt compared to later stage SZ. Later stage SZ had significant reductions in 
the PTR, BCC, CGC, ACR, FXST, CR, and average whole-brain FAt compared to 
controls. For FW differences, we observed significant elevations in the FX for early stage 
patients compared to HC and significant elevations in the PCR in later stages compared to 
HC. Our findings are consistent with the studies by Pasternak et al. (2015) and Oestreich 
et al. (2017), both examining FAt and FW relations in chronic SZ. Pasternak et al. (2015) 
found FAt reductions for frontal, temporal, and occipital lobes. Oestreich et al. (2017) 
similarly reported significant reductions in the PTR and BCC for chronic SZ. Both studies 
found limited abnormal elevations in extracellular space regarding FW. For FW 
differences, we observed significant elevations in the FX for early stages compared to HC 
and significant elevations in the PCR in later stages compared to HC. The FX, however, 
should be interpreted with caution due to its small structure and vulnerability to partial 
volume effects (Pai, Soltanian-Zadeh, & Hua, 2011; Prakash & Nowinski, 2006). 
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Our results suggest that WM aberrations may be more prominent and widespread 
as illness duration progresses. Although the largest effects were observed for tracts of 
interhemispheric, thalamocortical, and limbic regions, the current overall findings suggest 
a global mechanism for WM dysconnectivity in SZ, which is thought to contribute to 
characteristic symptoms of schizophrenia including cognitive deficits and clinical 
manifestations (Kubicki et al., 2007). 
 
Neurocognitive Correlates in FAt and FW 
We report significant differences between SZ and HC for verbal learning and 
memory, speed of processing, social cognition, and reasoning and problem solving. These 
domains have been well documented as impairments in SZ (Gur et al., 2001). We further 
examined associations between neurocognitive domains and WM specifically in SZ and 
report significant correlations between WM regions and working memory and 
attention/vigilance. Deficits in working memory have been extensively reported in SZ 
(Aleman, Hijman, de Haan, & Kahn, 1999).  
We report significant positive correlations between FAt of the FXST and PCR with 
working memory performance. FA reductions in the FX have been implicated in cognitive 
dysfunction and memory function in SZ (Nestor et al., 2007). The FX is a projection bundle 
connecting the medial temporal lobe to the hypothalamus and mamillary bodies (Catani & 
Thiebaut de Schotten, 2008). As our findings are in the FXST, which is a larger structure 
from ROI extraction, our results can be considered to be more stable than FX individually. 
The PCR has also been previously implicated in cognitive deficits. A recent meta-analysis 
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comparing mild cognitive impairment patients to HC report correlations between FA 
reductions in the PCR to cognitive deficits consistent with our results (Yu, Lam, & Lee, 
2017). The CR is a complex bundle of projection fibers connecting the cerebral cortex to 
subcortical structures as well as the brainstem via the internal capsule (Catani & Thiebaut 
de Schotten, 2008). The CR is thought to be involved in information processing, motor 
functions, and higher cognitive processes (Ćurčić-Blake et al., 2015; Schmahmann & 
Pandya, 2008). 
We also observed significant negative correlations between attention/vigilance and 
FW for the UNC. The UNC is an associative bundle connecting the anterior temporal lobe 
with the medial and lateral orbitofrontal cortex with both the frontal and temporal lobes 
(Catani & Thiebaut de Schotten, 2008) and is thought to be involved in various cognitive 
functioning including attention, emotion processing, memory, and language functions 
(Gaffan & Wilson, 2008; Ross, 2008; Singh et al., 2016). Our FW findings converge with 
a study by Singh et al. (2016) reporting associations between FA of the UNC and attention. 
However, we must also note that our study is the first to implicate a role for FW in cognitive 
deficits of early-course patients. 
 
Sociocognitive Correlates in FAt and FW 
Social cognitive impairments are considered to be core feature of SZ and is further 
demonstrated in our sample by the lower scores for patients compared to HC on the social 
cognition domain of the MATRICS. We found significant associations between WM 
regions and social cognition factors. Previous studies have shown associations between the 
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frontal cortex and thalamic regions and social functioning (Andreasen, 1997; Andreasen et 
al., 1999; Koshiyama et al., 2018; Miyata et al., 2010). The CR contains reciprocal 
connections from the thalamus to the cerebral cortex and has been shown to be involved in 
information processing and may potentially contribute to social and emotional functioning 
(Catani & Thiebaut de Schotten, 2008). 
To our knowledge, we report the first FAt and FW findings suggesting potential 
neural correlates of social cognition. We report significant associations in WM regions 
with the ToM social cognition factor. ToM has been shown to be related to lower severity 
in clinical symptomatology and associated with subjective quality of life (Maat, Fett, & 
Derks, 2012). Past research has shown that the medial and orbitofrontal cortices play major 
roles in ToM (Baron-Cohen et al., 1994; Fletcher et al., 1995). Scores in the other two 
factors failed to show any significant association with FAt and FW measures. 
We report significant positive correlations between higher FAt of the FXST and 
average whole-brain FAt with ToM. The FX is involved in the limbic system and 
specifically in the amygdala circuitry. The amygdala is also known to play a major role in 
social cognition and ToM (Michael F. Green, Horan, & Lee, 2015). We also report 
significant negative correlations between average whole-brain FW and the PCR. 
Koshiyama et al. (2018) found significant associations between FA of the ACR and social 
cognition, however, we report associations in the FAt of the PCR. As relations between 
WM and social cognition have been relatively unexplored, future studies are necessary to 




Clinical Correlates in FAt and FW 
We also investigated possible associations between clinical symptoms in SZ and 
WM integrity. Although we report no significant associations between FAt and FW for 
positive symptoms, we found a positive association between FAt reductions in WM of the 
EC with greater severity of negative symptoms. Negative symptoms in SZ are shown to be 
related to deficits in WM regions (Nestor et al., 2008; Skelly et al., 2008) as well as lower 
FA values (Mitelman et al., 2006; Sigmundsson et al., 2001; Viher et al., 2016). Viher et 
al. (2016) correspondingly reported associations between reduced FA in the EC with 
greater negative symptoms. The EC projects from the cortex to the basal ganglia, 
specifically to the striatum (Catani & Thiebaut de Schotten, 2008). Disrupted integrity in 
the EC constitute underlying pathologies which may lead to specific clinical 
symptomology present in schizophrenia.  
Furthermore, no significant effects of illness duration or medication dosage were 
identified in our study. Many cross-sectional DTI studies have also reported no detectable 
correlations between FA and medication (Samartzis et al., 2014). 
 
Implication of Findings 
We must note that our study is the first to implicate a role for FW in cognitive 
deficits of early-course patients. Lyall et al. (2017) previously demonstrated that elevated 
FW for first episode psychosis patients had a positive relationship with neurocognitive 
functioning after 12 weeks of antipsychotic treatment. To our knowledge, our study is also 
the first to examine FW in relation to social cognition and clinical symptoms. As FW is 
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considered to be an indirect measure of neuroinflammatory response during early stages of 
SZ, it is critical to detect biological markers prior to the onset of clinically detectable 
symptoms. The potential FW neural correlates that we identified in the current study may 




Some limitations of this study must be addressed. Although TBSS is widely used 
for WM analysis, this method has some limitations. TBSS reduces WM tracts into a 
skeleton and projects only the highest FA value along the projection often resulting in 
misregistration causing potential loss of information (Zalesky, 2011) and susceptibility to 
artifacts (Schwarz et al., 2014). Limitations also include partial volume effects, skeleton 
shapes, image noise level, and registration errors (Bach et al., 2014). Additionally, smaller 
tracts, such as the FX, are more susceptible to misalignment (Nestor et al., 2007). Although 
FA values are thought to represent the coherence of WM as well as the microstructural 
properties of axons including axon diameter, degree of myelination, and fiber packing 
density (Mukherjee, Berman, Chung, Hess, & Henry, 2008). It is furthermore important to 
also examine other diffusion indices such as AD, MD, and RD in SZ in order to attain a 
more complete understanding of how microstructural integrity influences the disrupted 
neural networks in SZ.  
We also acknowledge that our FAt and FW results must be interpreted with caution 
as FWI is a novel method. FW is considered to be an indirect measure of extracellular 
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fractional volume and should only be considered as a proxy for neuroinflammation 
(Pasternak et al., 2015). Analyses and consideration of other diffusivity measures may 
assist in identification of other potential underlying biological pathologies contributing to 
the present findings. Such pathologies may include reduced neuronal size (Rajkowska, 
Selemon, & Goldman-Rakic, 1998) which may be contributing to FAt reductions as well 
as atrophy caused by excessive synaptic pruning contributing to elevated FW results 
(Boksa, 2012). As we present the utilization of novel imaging methods, this research must 
be replicated in larger sample sizes in order to validate our exploratory analysis using FAt 
and FW measures. 
Our use of specific social cognition factors must also be addressed as a potential 
limitation. The three factors of social cognition were derived specifically from analyses of 
a larger subset of the present sample and potentially may only address social cognitive 
impairments tailored to the present sample. We must note that these factors may not be 
applicable to a broader population of SZ. 
Although the SZ and HC samples did not significantly differ, the smaller HC 
sample size may modulate the degree of WM microstructural changes detected due to 
power reduction. Whole-brain imaging studies with larger sample sizes are required to 
elucidate the associations between WM integrity and cognitive correlates. As early course 
SZ includes a wide range for illness duration (<8 years), the heterogeneity in our study may 
be preventing the prospect of detecting subtle WM microstructural changes. Age and stage 
of illness have been shown to effect WM patterns of brain changes (Ellison-Wright & 
Bullmore, 2009; Jones et al., 2006). An additional consideration to take in to account is 
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that all patients were medicated and relatively stable, hence our results may not be 
applicable to a broad SZ population. However, an exploratory correlation analysis 
indicated no significant associations between FAt and FW with medication, duration of 
illness, and age of onset in our main findings. 
Furthermore, due to the cross-sectional design of this analyses, we are unable to 
draw definitive conclusions about the underlying neural correlates observed in cognitive 
and clinical outcomes in SZ. We are also unable to state whether relationships between 
WM integrity and neurocognitive impairment and social dysfunction is causal. 
 
Future Directions 
We report baseline results from a longitudinal study focusing on CET. Future work 
in this sample will investigate the association between of CET and WM microstructural 
changes in addition to identifying potential improvements in neurocognitive and social 
cognitive domains as well as in clinical symptoms. Additionally, as we report correlations 
between WM and cognitive and clinical measures, we further aim to assess whether these 
correlates can be considered as potential biomarkers for predicting sensitivity and 
improvements to CET in the longitudinal dataset. Furthermore, future investigations on the 
longitudinal effects of CET post-treatment are warranted in order to assess durability as 







In conclusion, this study investigated WM microstructural differences in early 
course SZ in comparison to HC using measures of FAt and FW in ROIs across the whole 
brain. We further examined associations between WM and measures of cognition and 
clinical symptomatology. We report disrupted WM microstructure in SZ, specifically 
reductions in FAt ROIs along with elevated FW ROIs. To our knowledge, this is the first 
study to report findings for both FAt and FW neural correlates in neurocognition, social 
cognition, and negative symptoms for early course SZ. We hope our findings will 
contribute to a greater understanding of the neural networks underlying early course SZ 
symptomatology as changes in WM integrity may be a fundamental pathophysiological 







Supplemental Table 1: The effect sizes for FAt differences between SZ and HC. Data was 
covaried for age and sex. * indicates p<0.05. 
 
Region p-value Cohen’s d CI-Lower CI-Upper FDR p-value 
ACR 0.023 -0.631 -1.165 -0.092 0.14 
ALIC 0.141 -0.393 -0.921 0.138 0.294 
AverageFAt 0.077 -0.476 -1.006 0.057 0.214 
BCC 0.008* -0.741 -1.279 -0.198 0.108 
CC 0.028* -0.614 -1.147 -0.076 0.14 
CGC 0.009* -0.691 -1.227 -0.15 0.108 
CGH 0.391 -0.232 -0.758 0.295 0.543 
CR 0.043* -0.542 -1.073 -0.007 0.179 
CST 0.679 0.112 -0.414 0.637 0.738 
EC 0.818 -0.057 -0.582 0.468 0.818 
FX 0.376 -0.245 -0.771 0.283 0.543 
FXST 0.127 -0.427 -0.955 0.105 0.289 
GCC 0.072 -0.503 -1.033 0.031 0.214 
IC 0.226 -0.315 -0.842 0.214 0.353 
IFO 0.467 0.188 -0.339 0.713 0.614 
PCR 0.575 -0.149 -0.674 0.377 0.685 
PLIC 0.816 -0.062 -0.587 0.463 0.818 
PTR 0.013* -0.709 -1.245 -0.167 0.108 
RLIC 0.172 -0.353 -0.88 0.177 0.331 
SCC 0.491 -0.195 -0.72 0.332 0.614 
SCR 0.116 -0.423 -0.951 0.109 0.289 
SFO 0.209 -0.332 -0.859 0.197 0.348 
SLF 0.192 -0.34 -0.867 0.19 0.343 
SS 0.069 -0.506 -1.036 0.028 0.214 










Supplemental Table 2: The effect sizes for FW differences between SZ and HC. Data was 
covaried for age and sex. * indicates p<0.05. 
 
Region p-value Cohen’s d CI-Lower CI-Upper FDR p-value 
ACR 0.526 0.189 -0.338 0.714 0.758 
ALIC 0.961 -0.013 -0.538 0.512 0.961 
AverageFW 0.066 0.527 -0.008 1.058 0.219 
BCC 0.848 0.054 -0.471 0.579 0.922 
CC 0.546 0.168 -0.358 0.693 0.758 
CGC 0.061 0.55 0.014 1.081 0.219 
CGH 0.901 -0.034 -0.559 0.491 0.939 
CR 0.759 0.086 -0.44 0.611 0.886 
CST 0.78 0.079 -0.446 0.604 0.886 
EC 0.166 -0.386 -0.914 0.145 0.377 
FX 0.057 0.506 -0.028 1.036 0.219 
FXST 0.721 0.104 -0.422 0.629 0.886 
GCC 0.422 0.21 -0.317 0.735 0.703 
IC 0.34 0.253 -0.275 0.779 0.663 
IFO 0.491 0.186 -0.341 0.711 0.758 
PCR 0.012* 0.684 0.143 1.22 0.219 
PLIC 0.634 -0.13 -0.655 0.396 0.834 
PTR 0.039* 0.579 0.042 1.111 0.219 
RLIC 0.08 0.501 -0.033 1.031 0.222 
SCC 0.404 0.225 -0.302 0.751 0.703 
SCR 0.057 -0.504 -1.034 0.03 0.219 
SFO 0.345 0.258 -0.27 0.784 0.663 
SLF 0.14 -0.422 -0.95 0.11 0.35 
SS 0.07 0.492 -0.042 1.022 0.219 












Supplemental Table 3: The effect sizes for FAt differences between SZ stages and HC. 




Early Stage SZ vs 
HC 
Early Stage SZ vs Late 
Stage SZ 









ACR 0.370 -0.395 0.405 0.247 0.049* -0.738 
ALIC 0.507 -0.291 0.841 0.057 0.449 -0.446 
Average 
FAt 0.908 0.014 0.043* 0.720 0.043* -0.696 
BCC 0.120 -0.692 0.720 0.114 0.029* -0.755 
CC 0.245 -0.533 0.704 0.119 0.087 -0.641 
CGC 0.154 -0.561 0.620 0.164 0.028* -0.742 
CGH 0.236 0.354 0.020* 0.864 0.114 -0.509 
CR 0.627 -0.179 0.172 0.510 0.045* -0.705 
CST 0.780 0.270 0.780 0.210 0.865 0.052 
EC 0.675 0.130 0.675 0.325 0.675 -0.133 
FX 0.648 -0.341 0.648 -0.142 0.648 -0.203 
FXST 0.397 0.272 0.008* 0.979 0.017* -0.731 
GCC 0.448 -0.393 0.647 0.141 0.200 -0.543 
IC 0.725 -0.213 0.767 0.089 0.656 -0.366 
IFO 0.257 0.517 0.257 0.506 0.821 0.068 
PCR 0.283 0.399 0.080 0.837 0.283 -0.337 
PLIC 0.908 -0.163 0.908 -0.160 0.965 -0.016 
PTR 0.452 -0.321 0.123 0.561 0.010* -0.862 
RLIC 0.844 -0.083 0.323 0.445 0.267 -0.459 
SCC 0.860 -0.152 0.860 0.053 0.860 -0.210 
SCR 0.900 -0.059 0.169 0.503 0.130 -0.587 
SFO 0.682 -0.267 0.781 0.092 0.615 -0.355 
SLF 0.867 0.041 0.128 0.637 0.128 -0.484 
SS 0.886 -0.084 0.095 0.636 0.056* -0.661 







Supplemental Table 4: The effect sizes for FW differences between SZ stages and HC. 
Data was covaried for age and sex. * indicates p<0.05 for FDR correction for multiple 
comparisons. 
 
 Early Stage SZ 
vs HC 
Early Stage SZ vs Late 
Stage SZ 






p-value Cohen's d p-value Cohen's d 
ACR 0.519 -0.323 0.286 -0.539 0.286 -0.539 
ALIC 0.849 -0.179 0.849 -0.246 0.849 -0.246 
Average 
FW 
0.424 0.382 0.653 -0.129 0.653 -0.129 
BCC 0.993 0.061 0.993 0.003 0.993 0.003 
CC 0.817 0.122 0.817 -0.074 0.817 -0.074 
CGC 0.473 0.309 0.473 -0.191 0.473 -0.191 
CGH 0.825 -0.220 0.825 -0.245 0.825 -0.245 
CR 0.332 -0.472 0.144 -0.675 0.144 -0.675 
CST 0.938 0.028 0.938 -0.054 0.938 -0.054 
EC 0.268 -0.545 0.333 -0.294 0.333 -0.294 
FX 0.017 1.002 0.064 0.727 0.064 0.727 
FXST 0.809 0.134 0.809 0.071 0.809 0.071 
GCC 0.805 0.098 0.805 -0.185 0.805 -0.185 
IC 0.842 -0.050 0.260 -0.429 0.260 -0.429 
IFO 0.292 -0.384 0.059 -0.829 0.059 -0.829 
PCR 0.281 0.463 0.371 -0.288 0.371 -0.288 
PLIC 0.361 -0.477 0.361 -0.423 0.361 -0.423 
PTR 0.182 0.617 0.985 0.009 0.985 0.009 
RLIC 0.501 0.223 0.501 -0.264 0.501 -0.264 
SCC 0.782 0.176 0.782 -0.094 0.782 -0.094 
SCR 0.103 -0.752 0.287 -0.373 0.287 -0.373 
SFO 0.680 0.344 0.692 0.126 0.692 0.126 
SLF 0.350 -0.543 0.882 -0.050 0.882 -0.050 
SS 0.516 0.307 0.516 -0.194 0.516 -0.194 







Supplemental Table 5: The effect sizes for neurocognitive differences between SZ and 
HC. Data was covaried for age, sex, race, and education. * indicates p<0.05 for FDR 
correction for multiple comparisons.  
 
Region p-value Cohen’s d CI-Lower CI-Upper FDR p-value 
AV  0.386 -0.237 -0.763 0.290 0.450 
RPS  0.040 -0.566 -1.098 -0.030 0.070 
SC  0.005 -0.718 -1.255 -0.176 0.018 
SOP  0.009 -0.673 -1.208 -0.133 0.021 
VLBVM  0.246 0.316 -0.213 0.843 0.344 
VLHVL  0.004 -0.772 -1.311 -0.228 0.018 
WM  0.514 -0.167 -0.692 0.359 0.514 
 
 
Supplemental Table 6: Correlations between FAt ROIs and neurocognitive domains. Data 
was covaried for age, sex, race, and education. AV= attention/vigilance; RPS= reasoning 
and problem solving; SC= social cognition; VLBVM= visual learning & memory; 
VLHVL= verbal learning & memory; WM= working memory. * indicates p<0.05 for FDR 
correction for multiple comparisons. 
 
ROI-Neurocognition r value p-value FDR p-value 
ACR-AV  0.021 0.890 0.890 
ACR-RPS  0.084 0.584 0.890 
ACR-SC  -0.028 0.853 0.890 
ACR-SOP  0.126 0.403 0.890 
ACR-VLBVM  0.022 0.886 0.890 
ACR-VLHVL  0.047 0.754 0.890 
ACR-WM  0.022 0.882 0.890 
ALIC-AV  0.111 0.462 0.845 
ALIC-RPS  -0.083 0.585 0.845 
ALIC-SC  0.154 0.307 0.845 
ALIC-SOP  -0.074 0.623 0.845 
ALIC-VLBVM  -0.007 0.962 0.962 
ALIC-VLHVL  0.053 0.725 0.845 
ALIC-WM  0.071 0.639 0.845 
AverageFAt-AV  -0.020 0.896 0.896 
AverageFAt-RPS  0.051 0.738 0.896 
AverageFAt-SC  0.118 0.433 0.758 
AverageFAt-SOP  0.138 0.359 0.758 
	
47 
AverageFAt-VLBVM  0.133 0.377 0.758 
AverageFAt-VLHVL  0.037 0.808 0.896 
AverageFAt-WM  0.253 0.089 0.626 
BCC-AV  0.199 0.185 0.324 
BCC-RPS  0.238 0.115 0.269 
BCC-SC  -0.003 0.982 0.982 
BCC-SOP  0.256 0.086 0.269 
BCC-VLBVM  0.112 0.458 0.610 
BCC-VLHVL  0.096 0.523 0.610 
BCC-WM  0.256 0.086 0.269 
CC-AV  0.121 0.423 0.493 
CC-RPS  0.237 0.116 0.493 
CC-SC  0.059 0.698 0.698 
CC-SOP  0.168 0.264 0.493 
CC-VLBVM  0.146 0.333 0.493 
CC-VLHVL  0.140 0.352 0.493 
CC-WM  0.214 0.152 0.493 
CGC-AV  -0.237 0.113 0.792 
CGC-RPS  0.083 0.585 0.810 
CGC-SC  0.036 0.810 0.810 
CGC-SOP  0.083 0.584 0.810 
CGC-VLBVM  -0.076 0.616 0.810 
CGC-VLHVL  0.039 0.798 0.810 
CGC-WM  -0.148 0.327 0.810 
CGH-AV  0.090 0.551 0.965 
CGH-RPS  -0.204 0.178 0.524 
CGH-SC  0.182 0.224 0.524 
CGH-SOP  -0.003 0.986 0.986 
CGH-VLBVM  0.027 0.857 0.986 
CGH-VLHVL  -0.032 0.834 0.986 
CGH-WM  0.296 0.046 0.321 
CR-AV  0.014 0.924 0.936 
CR-RPS  0.084 0.582 0.936 
CR-SC  0.071 0.636 0.936 
CR-SOP  0.147 0.329 0.936 
CR-VLBVM  0.046 0.760 0.936 
CR-VLHVL  0.012 0.936 0.936 
CR-WM  0.187 0.212 0.936 
	
48 
CST-AV  -0.234 0.117 0.250 
CST-RPS  -0.233 0.123 0.250 
CST-SC  -0.046 0.760 0.887 
CST-SOP  -0.219 0.143 0.250 
CST-VLBVM  -0.123 0.415 0.580 
CST-VLHVL  -0.260 0.082 0.250 
CST-WM  0.017 0.909 0.909 
EC-AV  0.017 0.909 1.000 
EC-RPS  0.062 0.684 1.000 
EC-SC  0.194 0.196 1.000 
EC-SOP  0.050 0.740 1.000 
EC-VLBVM  0.097 0.522 1.000 
EC-VLHVL  0.000 1.000 1.000 
EC-WM  0.140 0.353 1.000 
FX-AV  0.094 0.534 0.813 
FX-RPS  0.162 0.287 0.813 
FX-SC  -0.260 0.081 0.568 
FX-SOP  0.070 0.642 0.813 
FX-VLBVM  -0.056 0.713 0.813 
FX-VLHVL  0.049 0.747 0.813 
FX-WM  -0.036 0.813 0.813 
FXST-AV  -0.110 0.467 0.788 
FXST-RPS  -0.164 0.282 0.788 
FXST-SC  0.096 0.526 0.788 
FXST-SOP  0.062 0.680 0.788 
FXST-VLBVM  0.041 0.788 0.788 
FXST-VLHVL  0.053 0.726 0.788 
FXST-WM  0.395 0.007 0.048* 
GCC-AV  -0.144 0.338 0.973 
GCC-RPS  0.131 0.388 0.973 
GCC-SC  -0.005 0.973 0.973 
GCC-SOP  -0.077 0.612 0.973 
GCC-VLBVM  0.007 0.964 0.973 
GCC-VLHVL  0.068 0.652 0.973 
GCC-WM  0.046 0.760 0.973 
IC-AV  0.098 0.515 0.948 
IC-RPS  -0.046 0.762 0.948 
IC-SC  0.135 0.372 0.948 
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IC-SOP  -0.024 0.874 0.948 
IC-VLBVM  0.050 0.739 0.948 
IC-VLHVL  0.010 0.948 0.948 
IC-WM  0.138 0.360 0.948 
IFO-AV  -0.035 0.816 0.816 
IFO-RPS  0.150 0.325 0.569 
IFO-SC  0.258 0.084 0.294 
IFO-SOP  0.099 0.512 0.597 
IFO-VLBVM  0.266 0.075 0.294 
IFO-VLHVL  0.177 0.238 0.555 
IFO-WM  0.119 0.430 0.597 
PCR-AV  0.084 0.578 0.578 
PCR-RPS  0.105 0.493 0.578 
PCR-SC  0.095 0.528 0.578 
PCR-SOP  0.240 0.108 0.379 
PCR-VLBVM  0.182 0.226 0.527 
PCR-VLHVL  0.144 0.338 0.578 
PCR-WM  0.463 0.001 0.010* 
PLIC-AV  0.182 0.226 0.998 
PLIC-RPS  0.010 0.948 0.998 
PLIC-SC  0.081 0.592 0.998 
PLIC-SOP  -0.129 0.392 0.998 
PLIC-VLBVM  0.000 0.998 0.998 
PLIC-VLHVL  -0.004 0.978 0.998 
PLIC-WM  0.051 0.736 0.998 
PTR-AV  0.106 0.481 0.674 
PTR-RPS  0.053 0.728 0.849 
PTR-SC  0.178 0.236 0.498 
PTR-SOP  0.181 0.227 0.498 
PTR-VLBVM  0.161 0.284 0.498 
PTR-VLHVL  -0.003 0.983 0.983 
PTR-WM  0.243 0.103 0.498 
RLIC-AV  -0.003 0.986 0.986 
RLIC-RPS  -0.061 0.688 0.964 
RLIC-SC  0.151 0.317 0.739 
RLIC-SOP  0.173 0.250 0.739 
RLIC-VLBVM  0.172 0.251 0.739 
RLIC-VLHVL  -0.027 0.859 0.986 
	
50 
RLIC-WM  0.070 0.642 0.964 
SCC-AV  0.125 0.408 0.692 
SCC-RPS  0.174 0.253 0.590 
SCC-SC  0.174 0.245 0.590 
SCC-SOP  0.062 0.682 0.692 
SCC-VLBVM  0.231 0.122 0.590 
SCC-VLHVL  0.060 0.692 0.692 
SCC-WM  0.062 0.680 0.692 
SCR-AV  -0.025 0.866 0.984 
SCR-RPS  0.037 0.809 0.984 
SCR-SC  0.159 0.290 0.984 
SCR-SOP  0.107 0.477 0.984 
SCR-VLBVM  0.009 0.951 0.984 
SCR-VLHVL  0.003 0.984 0.984 
SCR-WM  0.282 0.058 0.405 
SFO-AV  0.085 0.575 0.960 
SFO-RPS  -0.008 0.960 0.960 
SFO-SC  0.018 0.903 0.960 
SFO-SOP  0.013 0.934 0.960 
SFO-VLBVM  -0.109 0.471 0.960 
SFO-VLHVL  -0.040 0.794 0.960 
SFO-WM  0.175 0.243 0.960 
SLF-AV  -0.001 0.995 0.995 
SLF-RPS  0.076 0.617 0.912 
SLF-SC  0.068 0.652 0.912 
SLF-SOP  0.126 0.405 0.912 
SLF-VLBVM  0.097 0.521 0.912 
SLF-VLHVL  -0.003 0.983 0.995 
SLF-WM  0.160 0.289 0.912 
SS-AV  0.101 0.503 0.586 
SS-RPS  0.044 0.772 0.772 
SS-SC  0.102 0.500 0.586 
SS-SOP  0.181 0.229 0.586 
SS-VLBVM  0.107 0.479 0.586 
SS-VLHVL  -0.162 0.280 0.586 
SS-WM  0.179 0.232 0.586 
UNC-AV  -0.016 0.918 0.918 
UNC-RPS  0.024 0.874 0.918 
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UNC-SC  0.124 0.410 0.918 
UNC-SOP  -0.199 0.183 0.918 
UNC-VLBVM  -0.041 0.784 0.918 
UNC-VLHVL  -0.115 0.445 0.918 
UNC-WM  0.067 0.656 0.918 
 
 
Supplemental Table 7: Correlations between FW ROIs and neurocognitive domains. Data 
was covaried for age, sex, race, and education. AV= attention/vigilance; RPS= reasoning 
and problem solving; SC= social cognition; VLBVM= visual learning & memory; 
VLHVL= verbal learning & memory; WM= working memory. * indicates p<0.05 for FDR 
correction for multiple comparisons. 
 
ROI-Neurocognition r value p-value FDR p-value 
ACR-AV  0.048 0.753 0.852 
ACR-RPS  -0.029 0.852 0.852 
ACR-SC  0.034 0.823 0.852 
ACR-SOP  -0.085 0.574 0.852 
ACR-VLBVM  -0.123 0.415 0.852 
ACR-VLHVL  -0.065 0.665 0.852 
ACR-WM  -0.157 0.297 0.852 
ALIC-AV  -0.135 0.371 0.694 
ALIC-RPS  0.120 0.432 0.694 
ALIC-SC  0.059 0.694 0.694 
ALIC-SOP  0.075 0.620 0.694 
ALIC-VLBVM  -0.074 0.624 0.694 
ALIC-VLHVL  -0.099 0.510 0.694 
ALIC-WM  -0.161 0.286 0.694 
AverageFW-AV  -0.034 0.822 0.936 
AverageFW-RPS  0.046 0.764 0.936 
AverageFW-SC  0.106 0.481 0.936 
AverageFW-SOP  0.080 0.594 0.936 
AverageFW-VLBVM  0.012 0.936 0.936 
AverageFW-VLHVL  0.023 0.881 0.936 
AverageFW-WM  -0.110 0.465 0.936 
BCC-AV  -0.195 0.194 0.944 
BCC-RPS  -0.002 0.989 1.000 
BCC-SC  0.166 0.270 0.944 
BCC-SOP  -0.032 0.835 1.000 
	
52 
BCC-VLBVM  0.000 1.000 1.000 
BCC-VLHVL  -0.046 0.761 1.000 
BCC-WM  -0.123 0.414 0.966 
CC-AV  -0.127 0.399 0.882 
CC-RPS  0.023 0.882 0.882 
CC-SC  0.186 0.216 0.882 
CC-SOP  -0.042 0.783 0.882 
CC-VLBVM  -0.028 0.854 0.882 
CC-VLHVL  -0.044 0.769 0.882 
CC-WM  -0.103 0.494 0.882 
CGC-AV  0.000 0.999 0.999 
CGC-RPS  0.203 0.180 0.629 
CGC-SC  0.202 0.179 0.629 
CGC-SOP  -0.031 0.839 0.999 
CGC-VLBVM  0.104 0.490 0.999 
CGC-VLHVL  -0.001 0.995 0.999 
CGC-WM  0.016 0.914 0.999 
CGH-AV  -0.012 0.939 0.939 
CGH-RPS  -0.168 0.268 0.469 
CGH-SC  -0.025 0.868 0.939 
CGH-SOP  -0.111 0.460 0.644 
CGH-VLBVM  -0.282 0.058 0.202 
CGH-VLHVL  -0.200 0.182 0.424 
CGH-WM  -0.344 0.020 0.137 
CR-AV  0.044 0.773 0.982 
CR-RPS  0.004 0.982 0.982 
CR-SC  0.013 0.933 0.982 
CR-SOP  -0.068 0.651 0.982 
CR-VLBVM  -0.131 0.383 0.982 
CR-VLHVL  -0.058 0.703 0.982 
CR-WM  -0.230 0.124 0.871 
CST-AV  -0.138 0.360 0.504 
CST-RPS  0.216 0.154 0.504 
CST-SC  0.118 0.434 0.506 
CST-SOP  0.063 0.677 0.677 
CST-VLBVM  0.198 0.186 0.504 
CST-VLHVL  0.171 0.254 0.504 
CST-WM  -0.142 0.344 0.504 
	
53 
EC-AV  0.060 0.690 0.968 
EC-RPS  0.101 0.510 0.968 
EC-SC  0.001 0.993 0.993 
EC-SOP  0.088 0.557 0.968 
EC-VLBVM  0.138 0.359 0.968 
EC-VLHVL  -0.024 0.876 0.993 
EC-WM  -0.060 0.692 0.968 
FX-AV  -0.267 0.073 0.255 
FX-RPS  -0.237 0.116 0.271 
FX-SC  0.284 0.056 0.255 
FX-SOP  -0.070 0.644 0.871 
FX-VLBVM  -0.031 0.836 0.871 
FX-VLHVL  0.025 0.871 0.871 
FX-WM  -0.127 0.398 0.696 
FXST-AV  -0.042 0.783 0.890 
FXST-RPS  0.127 0.404 0.890 
FXST-SC  -0.021 0.890 0.890 
FXST-SOP  -0.045 0.764 0.890 
FXST-VLBVM  -0.124 0.410 0.890 
FXST-VLHVL  -0.082 0.585 0.890 
FXST-WM  -0.151 0.316 0.890 
GCC-AV  -0.088 0.560 0.978 
GCC-RPS  -0.004 0.978 0.978 
GCC-SC  0.180 0.229 0.978 
GCC-SOP  -0.050 0.739 0.978 
GCC-VLBVM  -0.110 0.464 0.978 
GCC-VLHVL  0.010 0.950 0.978 
GCC-WM  -0.067 0.658 0.978 
IC-AV  -0.046 0.759 0.852 
IC-RPS  0.109 0.474 0.852 
IC-SC  0.179 0.232 0.812 
IC-SOP  -0.066 0.664 0.852 
IC-VLBVM  -0.078 0.605 0.852 
IC-VLHVL  -0.028 0.852 0.852 
IC-WM  -0.280 0.059 0.416 
IFO-AV  0.105 0.487 0.798 
IFO-RPS  -0.005 0.973 0.973 
IFO-SC  -0.107 0.479 0.798 
	
54 
IFO-SOP  -0.048 0.751 0.876 
IFO-VLBVM  -0.086 0.570 0.798 
IFO-VLHVL  -0.099 0.509 0.798 
IFO-WM  -0.177 0.238 0.798 
PCR-AV  -0.041 0.784 0.915 
PCR-RPS  0.135 0.376 0.878 
PCR-SC  0.048 0.752 0.915 
PCR-SOP  0.016 0.915 0.915 
PCR-VLBVM  0.176 0.240 0.878 
PCR-VLHVL  0.138 0.358 0.878 
PCR-WM  -0.052 0.733 0.915 
PLIC-AV  -0.018 0.906 1.000 
PLIC-RPS  0.000 0.999 1.000 
PLIC-SC  0.000 1.000 1.000 
PLIC-SOP  -0.098 0.517 0.905 
PLIC-VLBVM  -0.234 0.118 0.324 
PLIC-VLHVL  -0.221 0.139 0.324 
PLIC-WM  -0.341 0.021 0.147 
PTR-AV  -0.014 0.927 0.927 
PTR-RPS  0.153 0.314 0.578 
PTR-SC  0.105 0.488 0.578 
PTR-SOP  0.103 0.495 0.578 
PTR-VLBVM  0.144 0.340 0.578 
PTR-VLHVL  0.257 0.085 0.578 
PTR-WM  0.115 0.444 0.578 
RLIC-AV  -0.020 0.897 0.948 
RLIC-RPS  0.077 0.614 0.948 
RLIC-SC  0.226 0.131 0.918 
RLIC-SOP  -0.010 0.948 0.948 
RLIC-VLBVM  0.014 0.928 0.948 
RLIC-VLHVL  0.154 0.306 0.948 
RLIC-WM  -0.084 0.580 0.948 
SCC-AV  -0.100 0.509 0.885 
SCC-RPS  0.031 0.840 0.885 
SCC-SC  0.146 0.332 0.885 
SCC-SOP  -0.062 0.680 0.885 
SCC-VLBVM  0.024 0.875 0.885 
SCC-VLHVL  -0.022 0.885 0.885 
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SCC-WM  -0.114 0.449 0.885 
SCR-AV  0.064 0.671 0.860 
SCR-RPS  -0.106 0.486 0.850 
SCR-SC  -0.046 0.763 0.860 
SCR-SOP  0.027 0.860 0.860 
SCR-VLBVM  -0.282 0.058 0.405 
SCR-VLHVL  -0.170 0.259 0.604 
SCR-WM  -0.206 0.168 0.589 
SFO-AV  -0.144 0.339 0.990 
SFO-RPS  -0.037 0.808 0.990 
SFO-SC  -0.010 0.947 0.990 
SFO-SOP  0.002 0.990 0.990 
SFO-VLBVM  -0.181 0.228 0.990 
SFO-VLHVL  -0.018 0.904 0.990 
SFO-WM  0.003 0.983 0.990 
SLF-AV  -0.028 0.852 0.852 
SLF-RPS  -0.289 0.055 0.385 
SLF-SC  0.108 0.473 0.827 
SLF-SOP  0.060 0.691 0.852 
SLF-VLBVM  0.029 0.847 0.852 
SLF-VLHVL  0.205 0.170 0.596 
SLF-WM  0.125 0.405 0.827 
SS-AV  -0.013 0.931 0.931 
SS-RPS  0.020 0.896 0.931 
SS-SC  -0.033 0.827 0.931 
SS-SOP  -0.113 0.452 0.931 
SS-VLBVM  0.113 0.455 0.931 
SS-VLHVL  0.071 0.637 0.931 
SS-WM  -0.044 0.772 0.931 
UNC-AV  -0.419 0.004 0.028* 
UNC-RPS  -0.108 0.481 0.673 
UNC-SC  0.199 0.185 0.557 
UNC-SOP  -0.176 0.242 0.557 
UNC-VLBVM  0.037 0.807 0.807 
UNC-VLHVL  0.150 0.318 0.557 





Supplemental Table 8: Correlations between FAt ROIs and social cognitive domains. 
Data was covaried for age, sex, and race. F1_MESCEIT= Emotion Management; 
F2_TOM= Theory of Mind; F3_ER= Emotion Perception. * indicates p<0.05 for FDR 
correction for multiple comparisons. 
 
ROI-Social Cognition r value p-value FDR p-value 
ACR-F1_MSCEIT 0.041 0.799 0.799 
ACR-F2_TOM 0.194 0.229 0.601 
ACR-F3_ER 0.136 0.401 0.601 
ALIC-F1_MSCEIT 0.120 0.458 0.458 
ALIC-F2_TOM 0.304 0.057 0.172 
ALIC-F3_ER 0.144 0.372 0.458 
AverageFAt-F1_MSCEIT 0.103 0.527 0.527 
AverageFAt-F2_TOM 0.457 0.003 0.010* 
AverageFAt-F3_ER 0.138 0.396 0.527 
BCC-F1_MSCEIT 0.124 0.446 0.669 
BCC-F2_TOM 0.166 0.304 0.669 
BCC-F3_ER 0.035 0.829 0.829 
CC-F1_MSCEIT 0.118 0.467 0.593 
CC-F2_TOM 0.174 0.283 0.593 
CC-F3_ER 0.087 0.593 0.593 
CGC-F1_MSCEIT -0.007 0.966 0.966 
CGC-F2_TOM 0.091 0.575 0.966 
CGC-F3_ER -0.053 0.742 0.966 
CGH-F1_MSCEIT 0.043 0.793 0.793 
CGH-F2_TOM 0.208 0.196 0.469 
CGH-F3_ER -0.163 0.312 0.469 
CR-F1_MSCEIT 0.059 0.715 0.715 
CR-F2_TOM 0.307 0.054 0.163 
CR-F3_ER 0.064 0.695 0.715 
CST-F1_MSCEIT -0.146 0.366 0.366 
CST-F2_TOM 0.230 0.153 0.366 
CST-F3_ER -0.162 0.315 0.366 
EC-F1_MSCEIT 0.188 0.244 0.366 
EC-F2_TOM 0.308 0.054 0.162 
EC-F3_ER 0.072 0.656 0.656 
FX-F1_MSCEIT -0.111 0.496 0.744 
FX-F2_TOM 0.114 0.483 0.744 
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FX-F3_ER -0.047 0.771 0.771 
FXST-F1_MSCEIT 0.199 0.218 0.327 
FXST-F2_TOM 0.486 0.002 0.005* 
FXST-F3_ER -0.011 0.948 0.948 
GCC-F1_MSCEIT 0.088 0.586 0.586 
GCC-F2_TOM 0.206 0.202 0.396 
GCC-F3_ER 0.180 0.264 0.396 
IC-F1_MSCEIT -0.018 0.914 0.988 
IC-F2_TOM 0.356 0.025 0.074 
IC-F3_ER -0.003 0.988 0.988 
IFO-F1_MSCEIT 0.129 0.427 0.641 
IFO-F2_TOM 0.262 0.102 0.307 
IFO-F3_ER -0.063 0.697 0.697 
PCR-F1_MSCEIT -0.043 0.791 0.791 
PCR-F2_TOM 0.263 0.101 0.303 
PCR-F3_ER -0.051 0.754 0.791 
PLIC-F1_MSCEIT -0.188 0.244 0.363 
PLIC-F2_TOM 0.321 0.044 0.132 
PLIC-F3_ER -0.147 0.363 0.363 
PTR-F1_MSCEIT 0.176 0.276 0.829 
PTR-F2_TOM 0.079 0.626 0.833 
PTR-F3_ER 0.034 0.833 0.833 
RLIC-F1_MSCEIT 0.128 0.429 0.643 
RLIC-F2_TOM 0.194 0.230 0.643 
RLIC-F3_ER 0.075 0.646 0.646 
SCC-F1_MSCEIT 0.108 0.507 0.594 
SCC-F2_TOM 0.100 0.539 0.594 
SCC-F3_ER 0.087 0.594 0.594 
SCR-F1_MSCEIT 0.102 0.529 0.793 
SCR-F2_TOM 0.341 0.032 0.096 
SCR-F3_ER 0.011 0.945 0.945 
SFO-F1_MSCEIT 0.203 0.208 0.208 
SFO-F2_TOM 0.280 0.080 0.134 
SFO-F3_ER 0.272 0.089 0.134 
SLF-F1_MSCEIT 0.041 0.801 0.801 
SLF-F2_TOM 0.111 0.494 0.741 
SLF-F3_ER 0.120 0.461 0.741 
SS-F1_MSCEIT 0.182 0.261 0.783 
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SS-F2_TOM 0.103 0.527 0.790 
SS-F3_ER 0.036 0.826 0.826 
UNC-F1_MSCEIT 0.023 0.888 0.888 
UNC-F2_TOM 0.350 0.028 0.083 
UNC-F3_ER 0.042 0.795 0.888 
 
 
Supplemental Table 9: Correlations between FW ROIs and social cognitive domains. 
Data was covaried for age, sex, and race. F1_MESCEIT= Emotion Management; 
F2_TOM= Theory of Mind; F3_ER= Emotion Perception. * indicates p<0.05 for FDR 
correction for multiple comparisons. 
 
ROI-Social Cognition r value p-value FDR p-value 
ACR-F1_MSCEIT -0.041 0.799 0.799 
ACR-F2_TOM -0.317 0.047 0.140 
ACR-F3_ER 0.153 0.345 0.517 
ALIC-F1_MSCEIT -0.178 0.271 0.271 
ALIC-F2_TOM -0.305 0.056 0.169 
ALIC-F3_ER -0.223 0.166 0.248 
AverageFW-F1_MSCEIT -0.135 0.405 0.608 
AverageFW-F2_TOM -0.413 0.008 0.025* 
AverageFW-F3_ER -0.064 0.694 0.694 
BCC-F1_MSCEIT -0.111 0.496 0.505 
BCC-F2_TOM -0.224 0.164 0.492 
BCC-F3_ER 0.108 0.505 0.505 
CC-F1_MSCEIT -0.037 0.819 0.819 
CC-F2_TOM -0.255 0.113 0.338 
CC-F3_ER 0.078 0.633 0.819 
CGC-F1_MSCEIT -0.031 0.851 0.851 
CGC-F2_TOM -0.316 0.047 0.142 
CGC-F3_ER -0.044 0.785 0.851 
CGH-F1_MSCEIT -0.065 0.691 0.691 
CGH-F2_TOM -0.136 0.401 0.602 
CGH-F3_ER -0.333 0.036 0.109 
CR-F1_MSCEIT -0.185 0.252 0.378 
CR-F2_TOM -0.361 0.023 0.068 
CR-F3_ER 0.037 0.819 0.819 
CST-F1_MSCEIT -0.205 0.205 0.307 
CST-F2_TOM -0.339 0.033 0.098 
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CST-F3_ER -0.124 0.444 0.444 
EC-F1_MSCEIT -0.066 0.685 0.743 
EC-F2_TOM -0.279 0.081 0.243 
EC-F3_ER 0.053 0.743 0.743 
FX-F1_MSCEIT 0.012 0.942 0.942 
FX-F2_TOM -0.053 0.743 0.942 
FX-F3_ER 0.060 0.712 0.942 
FXST-F1_MSCEIT -0.208 0.197 0.349 
FXST-F2_TOM -0.193 0.233 0.349 
FXST-F3_ER -0.116 0.476 0.476 
GCC-F1_MSCEIT -0.008 0.962 0.962 
GCC-F2_TOM -0.361 0.023 0.068 
GCC-F3_ER 0.058 0.723 0.962 
IC-F1_MSCEIT 0.017 0.915 0.915 
IC-F2_TOM -0.371 0.019 0.057 
IC-F3_ER -0.108 0.504 0.756 
IFO-F1_MSCEIT -0.062 0.703 0.703 
IFO-F2_TOM -0.205 0.203 0.460 
IFO-F3_ER -0.165 0.307 0.460 
PCR-F1_MSCEIT -0.147 0.363 0.545 
PCR-F2_TOM -0.414 0.008 0.025* 
PCR-F3_ER 0.042 0.797 0.797 
PLIC-F1_MSCEIT 0.118 0.467 0.562 
PLIC-F2_TOM -0.283 0.077 0.230 
PLIC-F3_ER 0.094 0.562 0.562 
PTR-F1_MSCEIT 0.037 0.820 0.820 
PTR-F2_TOM -0.271 0.091 0.272 
PTR-F3_ER -0.169 0.297 0.446 
RLIC-F1_MSCEIT 0.106 0.512 0.687 
RLIC-F2_TOM -0.096 0.553 0.687 
RLIC-F3_ER -0.065 0.687 0.687 
SCC-F1_MSCEIT 0.086 0.594 0.867 
SCC-F2_TOM -0.168 0.300 0.867 
SCC-F3_ER -0.027 0.867 0.867 
SCR-F1_MSCEIT -0.155 0.339 0.550 
SCR-F2_TOM 0.010 0.951 0.951 
SCR-F3_ER -0.146 0.367 0.550 
SFO-F1_MSCEIT -0.244 0.129 0.386 
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SFO-F2_TOM 0.091 0.577 0.865 
SFO-F3_ER -0.025 0.877 0.877 
SLF-F1_MSCEIT -0.085 0.601 0.706 
SLF-F2_TOM 0.185 0.252 0.706 
SLF-F3_ER -0.061 0.706 0.706 
SS-F1_MSCEIT 0.009 0.954 0.954 
SS-F2_TOM -0.186 0.251 0.752 
SS-F3_ER 0.031 0.849 0.954 
UNC-F1_MSCEIT -0.065 0.691 0.691 
UNC-F2_TOM -0.143 0.377 0.691 
UNC-F3_ER -0.077 0.638 0.691 
 
 
Supplemental Table 10: Correlations between FAt ROIs and clinical measures. Data was 
covaried for age, and sex. SAPS= Scale for the Assessment of Positive Symptoms; SANS= 
Scale for the Assessment of Negative Symptoms. * indicates p<0.05 for FDR correction 
for multiple comparisons. 
 
ROI-Clinical Symptoms r value p-value FDR p-value 
ACR-SAPS 0.260 0.084 0.169 
ACR-SANS -0.092 0.545 0.545 
ALIC-SAPS -0.001 0.997 0.997 
ALIC-SANS -0.072 0.636 0.997 
AverageFAt-SAPS 0.159 0.297 0.297 
AverageFAt-SANS -0.176 0.247 0.297 
BCC-SAPS 0.299 0.046 0.092 
BCC-SANS -0.072 0.639 0.639 
CC-SAPS 0.272 0.071 0.141 
CC-SANS -0.139 0.360 0.360 
CGC-SAPS 0.257 0.089 0.177 
CGC-SANS -0.059 0.698 0.698 
CGH-SAPS -0.219 0.147 0.294 
CGH-SANS -0.109 0.476 0.476 
CR-SAPS 0.193 0.204 0.408 
CR-SANS -0.119 0.433 0.433 
CST-SAPS -0.124 0.416 0.833 
CST-SANS -0.002 0.989 0.989 
EC-SAPS -0.027 0.859 0.859 
EC-SANS -0.181 0.233 0.466 
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FX-SAPS 0.215 0.156 0.312 
FX-SANS -0.020 0.897 0.897 
FXST-SAPS -0.041 0.788 0.788 
FXST-SANS -0.082 0.591 0.788 
GCC-SAPS 0.231 0.127 0.254 
GCC-SANS -0.005 0.972 0.972 
IC-SAPS 0.034 0.824 0.824 
IC-SANS -0.138 0.366 0.733 
IFO-SAPS 0.093 0.542 0.542 
IFO-SANS -0.123 0.420 0.542 
PCR-SAPS 0.213 0.160 0.298 
PCR-SANS -0.158 0.298 0.298 
PLIC-SAPS -0.033 0.832 0.832 
PLIC-SANS -0.108 0.478 0.832 
PTR-SAPS 0.186 0.220 0.441 
PTR-SANS -0.067 0.661 0.661 
RLIC-SAPS 0.113 0.457 0.457 
RLIC-SANS -0.225 0.137 0.273 
SCC-SAPS 0.069 0.653 0.653 
SCC-SANS -0.249 0.099 0.198 
SCR-SAPS 0.110 0.472 0.616 
SCR-SANS -0.077 0.616 0.616 
SFO-SAPS 0.085 0.577 0.848 
SFO-SANS -0.029 0.848 0.848 
SLF-SAPS 0.318 0.034 0.068 
SLF-SANS -0.038 0.805 0.805 
SS-SAPS 0.057 0.708 0.708 
SS-SANS -0.200 0.188 0.376 
UNC-SAPS -0.123 0.419 0.419 











Supplemental Table 11: Correlations between FW ROIs and clinical measures. Data was 
covaried for age, and sex. SAPS= Scale for the Assessment of Positive Symptoms; SANS= 
Scale for the Assessment of Negative Symptoms. * indicates p<0.05 for FDR correction 
for multiple comparisons. 
 
ROI-Clinical Symptoms r value p-value FDR p-value 
ACR-SAPS -0.160 0.292 0.585 
ACR-SANS -0.015 0.923 0.923 
ALIC-SAPS 0.241 0.110 0.221 
ALIC-SANS 0.140 0.358 0.358 
AverageFW-SAPS -0.222 0.143 0.286 
AverageFW-SANS 0.012 0.936 0.936 
BCC-SAPS -0.082 0.593 0.593 
BCC-SANS -0.170 0.264 0.528 
CC-SAPS -0.103 0.498 0.498 
CC-SANS -0.135 0.374 0.498 
CGC-SAPS -0.146 0.337 0.674 
CGC-SANS -0.001 0.994 0.994 
CGH-SAPS -0.026 0.864 0.864 
CGH-SANS 0.063 0.682 0.864 
CR-SAPS -0.148 0.329 0.658 
CR-SANS -0.050 0.745 0.745 
CST-SAPS 0.232 0.124 0.142 
CST-SANS 0.222 0.142 0.142 
EC-SAPS -0.011 0.942 0.942 
EC-SANS 0.337 0.024 0.048* 
FX-SAPS -0.132 0.387 0.774 
FX-SANS -0.039 0.799 0.799 
FXST-SAPS 0.031 0.841 0.995 
FXST-SANS 0.001 0.995 0.995 
GCC-SAPS -0.044 0.772 0.772 
GCC-SANS -0.074 0.627 0.772 
IC-SAPS 0.015 0.923 0.923 
IC-SANS 0.027 0.861 0.923 
IFO-SAPS -0.176 0.247 0.494 
IFO-SANS 0.065 0.671 0.671 
PCR-SAPS -0.054 0.725 0.725 
PCR-SANS -0.089 0.558 0.725 
	
63 
PLIC-SAPS 0.083 0.586 0.859 
PLIC-SANS 0.027 0.859 0.859 
PTR-SAPS 0.036 0.812 0.812 
PTR-SANS -0.087 0.571 0.812 
RLIC-SAPS -0.065 0.671 0.671 
RLIC-SANS -0.115 0.449 0.671 
SCC-SAPS -0.098 0.522 0.948 
SCC-SANS 0.010 0.948 0.948 
SCR-SAPS 0.118 0.440 0.880 
SCR-SANS 0.008 0.961 0.961 
SFO-SAPS -0.116 0.447 0.447 
SFO-SANS -0.272 0.071 0.143 
SLF-SAPS -0.049 0.750 0.950 
SLF-SANS -0.010 0.950 0.950 
SS-SAPS -0.276 0.067 0.134 
SS-SANS -0.024 0.876 0.876 
UNC-SAPS -0.159 0.297 0.593 
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